AARD · Company research
Aardvark Therapeutics, Inc. Common Stock (AARD): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
37records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 13, 2026 in Aardvark Therapeutics, Inc. Lawsuit - AARD - FinancialContent | SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 13, 2026 in Aardvark Therapeutics, Inc. Lawsuit - AARD FinancialContent | View source ↗ | FinancialContent | Oct 13, 2026 | neutral | 0 | 0.6 |
| CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026 - Business Wire | CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026 Business Wire | View source ↗ | Business Wire | Oct 13, 2026 | neutral | 0 | 0.6 |
| Levi & Korsinsky Reminds Aardvark Therapeutics Investors of - GlobeNewswire | Levi & Korsinsky Reminds Aardvark Therapeutics Investors of GlobeNewswire | View source ↗ | GlobeNewswire | Oct 12, 2026 | neutral | 0 | 0.6 |
| Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits | Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts Stocktwits | View source ↗ | Stocktwits | Oct 11, 2026 | neutral | 0 | 0.6 |
| URGENT AARDVARK DEADLINE: Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 13th | A class action lawsuit has been filed against Aardvark Therapeutics in the U.S. District Court for the Southern District of California. The lawsuit alleges that defendants made materially false and misleading statements in the company's IPO registration statement and throughout the class period (February 13, 2025 to May 14, 2026), specifically regarding the safety and commercial prospects of their drug ARD-101. Investors who purchased shares during this period can apply to be lead plaintiff by October 13, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 10, 2026 | bearish | -1 | 1 |
| AARD 4-DAY DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 13, 2026 Lead Plaintiff Deadline - HBSS | Hagens Berman announces a securities class action lawsuit against Aardvark Therapeutics for allegedly making materially false statements about ARD-101's safety. The company failed to disclose cardiac observations during trials, leading to a voluntary pause of the Phase 3 HERO trial in February 2026 (56% stock decline) and an FDA clinical hold in May 2026 (32.1% additional decline). Investors with substantial losses have until October 13, 2026, to become lead plaintiffs. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bearish | -1 | 1 |
| Aardvark Therapeutics Adds Veteran Independent Board Director - The Globe and Mail | Aardvark Therapeutics Adds Veteran Independent Board Director The Globe and Mail | View source ↗ | The Globe and Mail | Oct 9, 2026 | neutral | 0 | 0.6 |
| AARD UPCOMING DEADLINE: Levi & Korsinsky Alerts Aardvark Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm - FinancialContent | AARD UPCOMING DEADLINE: Levi & Korsinsky Alerts Aardvark Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm FinancialContent | View source ↗ | FinancialContent | Oct 9, 2026 | neutral | 0 | 0.6 |
| Insiders Give Up US$97k As Aardvark Therapeutics Stock Drops To US$4.71 - Simply Wall Street | Insiders Give Up US$97k As Aardvark Therapeutics Stock Drops To US$4.71 Simply Wall Street | View source ↗ | Simply Wall Street | Oct 9, 2026 | neutral | 0 | 0.6 |
| AARD DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARD | Rosen Law Firm announces a securities class action lawsuit against Aardvark Therapeutics, Inc. for allegedly making materially false and misleading statements regarding the safety and prospects of its drug ARD-101. Investors who purchased securities during the IPO on February 13, 2025 or between February 13, 2025 and May 14, 2026 may be eligible to join the class action. The deadline to serve as lead plaintiff is October 13, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bearish | -1 | 1 |
| AARD DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARD | Rosen Law Firm announces a securities class action lawsuit against Aardvark Therapeutics, Inc. for allegedly making materially false and misleading statements regarding the safety and prospects of its drug ARD-101. Investors who purchased securities during the IPO on February 13, 2025 or between February 13, 2025 and May 14, 2026 may be eligible to join the class action. The deadline to serve as lead plaintiff is October 13, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bearish | -1 | 1 |
| AARD Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aardvark Therapeutics Securities Lawsuit - Contact SueWallSt - PR Newswire | AARD Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aardvark Therapeutics Securities Lawsuit - Contact SueWallSt PR Newswire | View source ↗ | PR Newswire | Oct 8, 2026 | neutral | 0 | 0.6 |
| Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your Behalf | Grabar Law Office is investigating securities fraud and fiduciary duty breach claims against four companies: Aardvark Therapeutics for allegedly misrepresenting the safety profile of its drug candidate ARD-101 before a clinical hold was placed; Coastal Financial Corporation for failing to disclose deterioration in its CCBX partner loan portfolio and credit losses; Erasca, Inc. for making misleading statements about its ERAS-0015 therapy and improper comparisons to competitors; and New Era Energy & Digital for overstating progress on its data center project and allegedly engaging in fraudulent oil-and-gas schemes. | View source ↗ | GlobeNewswire Inc. | Oct 8, 2026 | bearish | -1 | 1 |
| Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your Behalf | Grabar Law Office is investigating securities fraud and fiduciary duty breach claims against four companies: Aardvark Therapeutics for allegedly misrepresenting the safety profile of its drug candidate ARD-101 before a clinical hold was placed; Coastal Financial Corporation for failing to disclose deterioration in its CCBX partner loan portfolio and credit losses; Erasca, Inc. for making misleading statements about its ERAS-0015 therapy and improper comparisons to competitors; and New Era Energy & Digital for overstating progress on its data center project and allegedly engaging in fraudulent oil-and-gas schemes. | View source ↗ | GlobeNewswire Inc. | Oct 8, 2026 | bearish | -1 | 1 |
| Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and New Era Energy & Digital, Inc. (NASDAQ: NUAI): Grabar Law Office is Investigating Claims on Your Behalf | Grabar Law Office is investigating securities fraud and fiduciary duty breach claims against four companies: Aardvark Therapeutics for allegedly misrepresenting the safety profile of its drug candidate ARD-101 before a clinical hold was placed; Coastal Financial Corporation for failing to disclose deterioration in its CCBX partner loan portfolio and credit losses; Erasca, Inc. for making misleading statements about its ERAS-0015 therapy and improper comparisons to competitors; and New Era Energy & Digital for overstating progress on its data center project and allegedly engaging in fraudulent oil-and-gas schemes. | View source ↗ | GlobeNewswire Inc. | Oct 8, 2026 | bearish | -1 | 1 |
| Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors | Aardvark Therapeutics appointed David Zhang, Ph.D., MBA, as an independent board director, bringing over 25 years of clinical development and regulatory expertise from companies including MyoKardia, Genentech/Roche, Alumis, and Abivax. Zhang will support Aardvark's regulatory strategy for ARD-101, its lead candidate for Prader-Willi Syndrome treatment, at a critical juncture following an FDA clinical hold. | View source ↗ | GlobeNewswire Inc. | Oct 8, 2026 | neutral | 0 | 1 |
| Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors | Aardvark Therapeutics appointed David Zhang, Ph.D., MBA, as an independent board director, bringing over 25 years of clinical development and regulatory expertise from companies including MyoKardia, Genentech/Roche, Alumis, and Abivax. Zhang will support Aardvark's regulatory strategy for ARD-101, its lead candidate for Prader-Willi Syndrome treatment, at a critical juncture following an FDA clinical hold. | View source ↗ | GlobeNewswire Inc. | Oct 8, 2026 | neutral | 0 | 1 |
| Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors | Aardvark Therapeutics appointed David Zhang, Ph.D., MBA, as an independent board director, bringing over 25 years of clinical development and regulatory expertise from companies including MyoKardia, Genentech/Roche, Alumis, and Abivax. Zhang will support Aardvark's regulatory strategy for ARD-101, its lead candidate for Prader-Willi Syndrome treatment, at a critical juncture following an FDA clinical hold. | View source ↗ | GlobeNewswire Inc. | Oct 8, 2026 | neutral | 0 | 1 |
| AARD Shareholder Alert: October 13, 2026 Lead Plaintiff Deadline in Aardvark Therapeutics, Inc. Securities Class Action - Contact Levi & Korsinsky - Morningstar | AARD Shareholder Alert: October 13, 2026 Lead Plaintiff Deadline in Aardvark Therapeutics, Inc. Securities Class Action - Contact Levi & Korsinsky Morningstar | View source ↗ | Morningstar | Oct 7, 2026 | neutral | 0 | 0.6 |
| Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm | A class action lawsuit has been filed against Aardvark Therapeutics, Inc. alleging securities fraud. The complaint claims that offering documents contained untrue statements and that the company made materially false and misleading statements regarding the safety and prospects of its drug ARD-101. Investors who purchased shares during the IPO on February 13, 2025, or between that date and May 14, 2026, may be eligible to join the case. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bearish | -1 | 1 |
| Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm | A class action lawsuit has been filed against Aardvark Therapeutics, Inc. alleging securities fraud. The complaint claims that offering documents contained untrue statements and that the company made materially false and misleading statements regarding the safety and prospects of its drug ARD-101. Investors who purchased shares during the IPO on February 13, 2025, or between that date and May 14, 2026, may be eligible to join the case. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bearish | -1 | 1 |
| Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); and ... - pmg-ky3.com | Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); and ... pmg-ky3.com | View source ↗ | pmg-ky3.com | Oct 6, 2026 | neutral | 0 | 0.6 |
| AARDVARK THERAPEUTICS (NASDAQ: AARD) SECURITIES CLASS ACTION: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Investors to Secure Counsel Before Important October 13 Deadline | Rosen Law Firm announces a securities class action lawsuit against Aardvark Therapeutics, with an October 13, 2026 deadline for investors to serve as lead plaintiff. The lawsuit alleges that defendants made materially false and misleading statements regarding the safety and prospects of their drug candidate ARD-101, causing investor damages when the true details emerged. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bearish | -1 | 1 |
| AARDVARK THERAPEUTICS (NASDAQ: AARD) SECURITIES CLASS ACTION: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Investors to Secure Counsel Before Important October 13 Deadline | Rosen Law Firm announces a securities class action lawsuit against Aardvark Therapeutics, with an October 13, 2026 deadline for investors to serve as lead plaintiff. The lawsuit alleges that defendants made materially false and misleading statements regarding the safety and prospects of their drug candidate ARD-101, causing investor damages when the true details emerged. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bearish | -1 | 1 |
| AARD Deadline Alert: Levi & Korsinsky Reminds Aardvark - GlobeNewswire | AARD Deadline Alert: Levi & Korsinsky Reminds Aardvark GlobeNewswire | View source ↗ | GlobeNewswire | Oct 5, 2026 | neutral | 0 | 0.6 |
| Aardvark Therapeutics (AARD) Slides 5.31% to $4.99 as Shares Retreat Toward Lower Support - Earnings Miss Risk - https://www.dars.gov.et/ | Aardvark Therapeutics (AARD) Slides 5.31% to $4.99 as Shares Retreat Toward Lower Support - Earnings Miss Risk https://www.dars.gov.et/ | View source ↗ | https://www.dars.gov.et/ | Oct 5, 2026 | neutral | 0 | 0.6 |
| AARDVARK DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARD | Rosen Law Firm has announced multiple securities class action lawsuits against Aardvark Therapeutics, FuelCell Energy, and XTI Aerospace. The primary case involves Aardvark Therapeutics, where investors claim the company made materially false statements about the safety and prospects of its ARD-101 drug candidate in its IPO registration statement and throughout the class period. Investors have until October 13, 2026 to become lead plaintiffs in the Aardvark case. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bearish | -1 | 1 |
| AARDVARK DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARD | Rosen Law Firm has announced multiple securities class action lawsuits against Aardvark Therapeutics, FuelCell Energy, and XTI Aerospace. The primary case involves Aardvark Therapeutics, where investors claim the company made materially false statements about the safety and prospects of its ARD-101 drug candidate in its IPO registration statement and throughout the class period. Investors have until October 13, 2026 to become lead plaintiffs in the Aardvark case. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bearish | -1 | 1 |
| Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm | A class action lawsuit has been filed against Aardvark Therapeutics, Inc. alleging securities fraud related to its February 2025 IPO and subsequent period through May 2026. The complaint claims the company made materially false and misleading statements about the safety and prospects of its drug candidate ARD-101, and that offering documents were negligently prepared. Investors who purchased shares during the class period are encouraged to join the lawsuit. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bearish | -1 | 1 |
| Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm | A class action lawsuit has been filed against Aardvark Therapeutics, Inc. alleging securities fraud related to its February 2025 IPO and subsequent period through May 2026. The complaint claims the company made materially false and misleading statements about the safety and prospects of its drug candidate ARD-101, and that offering documents were negligently prepared. Investors who purchased shares during the class period are encouraged to join the lawsuit. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bearish | -1 | 1 |
| AARD UPCOMING DEADLINE: SueWallSt Alerts Aardvark Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm - PR Newswire | AARD UPCOMING DEADLINE: SueWallSt Alerts Aardvark Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm PR Newswire | View source ↗ | PR Newswire | Oct 1, 2026 | neutral | 0 | 0.6 |
| AARD Stock News: Robbins LLP Reminds Aardvark Therapeutics, Inc. Stockholders to Contact the Firm Before the October 13, 2026 Lead Plaintiff Deadline - Morningstar | AARD Stock News: Robbins LLP Reminds Aardvark Therapeutics, Inc. Stockholders to Contact the Firm Before the October 13, 2026 Lead Plaintiff Deadline Morningstar | View source ↗ | Morningstar | Sep 30, 2026 | neutral | 0 | 0.6 |
| AARDVARK THERAPEUTICS, INC. (AARD) SHAREHOLDER ALERT - GlobeNewswire | AARDVARK THERAPEUTICS, INC. (AARD) SHAREHOLDER ALERT GlobeNewswire | View source ↗ | GlobeNewswire | Sep 30, 2026 | neutral | 0 | 0.6 |
| Levi & Korsinsky Reminds Aardvark Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 13, 2026 - AARD - Morningstar | Levi & Korsinsky Reminds Aardvark Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 13, 2026 - AARD Morningstar | View source ↗ | Morningstar | Sep 23, 2026 | neutral | 0 | 0.6 |
| AARD DEADLINE: Levi & Korsinsky Reminds Aardvark Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline - PR Newswire | AARD DEADLINE: Levi & Korsinsky Reminds Aardvark Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline PR Newswire | View source ↗ | PR Newswire | Aug 26, 2026 | neutral | 0 | 0.6 |
| Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Berman - PR Newswire | Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Berman PR Newswire | View source ↗ | PR Newswire | Jul 30, 2026 | neutral | 0 | 0.6 |
| AARD Stock Plummets After Hours As Cardiac Safety Concerns Trigger FDA Hold On Late-stage Program - Stocktwits | AARD Stock Plummets After Hours As Cardiac Safety Concerns Trigger FDA Hold On Late-stage Program Stocktwits | View source ↗ | Stocktwits | May 14, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.